[go: up one dir, main page]

CO2018003471A2 - Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue - Google Patents

Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue

Info

Publication number
CO2018003471A2
CO2018003471A2 CONC2018/0003471A CO2018003471A CO2018003471A2 CO 2018003471 A2 CO2018003471 A2 CO 2018003471A2 CO 2018003471 A CO2018003471 A CO 2018003471A CO 2018003471 A2 CO2018003471 A2 CO 2018003471A2
Authority
CO
Colombia
Prior art keywords
dengue viral
compounds
inhibitors
viral replication
disubstituted derivatives
Prior art date
Application number
CONC2018/0003471A
Other languages
English (en)
Inventor
Bart Rudolf Romanie Kesteleyn
Tim Hugo Maria Jonckers
Arnaud Didier M Marchand
Jean-François Bonfanti
Pierre Jean-Marie Bernard Raboisson
Dorothée Alice Marie-Eve Bardiot
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of CO2018003471A2 publication Critical patent/CO2018003471A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a compuestos indólicos mono- o disustituidos, a métodos para prevenir o tratar infecciones virales por dengue utilizando dichos compuestos y también se refiere a dichos compuestos para su uso como una medicina, más preferentemente para su uso como una medicina para tratar o prevenir infecciones virales por dengue. La presente invención se refiere además a composiciones farmacéuticas o preparados combinados de los compuestos, a las composiciones o preparados para su uso como una medicina, más preferentemente para la prevención o el tratamiento de infecciones virales por dengue. La invención también se refiere a procesos para la preparación de los compuestos.
CONC2018/0003471A 2015-09-16 2018-03-28 Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue CO2018003471A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15185523 2015-09-16
EP16163472 2016-04-01
PCT/EP2016/071845 WO2017046255A1 (en) 2015-09-16 2016-09-15 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors

Publications (1)

Publication Number Publication Date
CO2018003471A2 true CO2018003471A2 (es) 2018-07-10

Family

ID=56926217

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0003471A CO2018003471A2 (es) 2015-09-16 2018-03-28 Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue

Country Status (29)

Country Link
US (1) US10765662B2 (es)
EP (1) EP3350162B1 (es)
JP (2) JP7050666B2 (es)
KR (1) KR102646174B1 (es)
CN (1) CN108473422B (es)
AU (1) AU2016324982B2 (es)
CA (1) CA2996979C (es)
CL (1) CL2018000696A1 (es)
CO (1) CO2018003471A2 (es)
CR (1) CR20180213A (es)
DK (1) DK3350162T3 (es)
EA (1) EA035663B1 (es)
EC (1) ECSP18020055A (es)
ES (1) ES2893298T3 (es)
HR (1) HRP20211352T1 (es)
HU (1) HUE055870T2 (es)
IL (1) IL258043B (es)
JO (1) JOP20160198B1 (es)
LT (1) LT3350162T (es)
MA (1) MA42810A (es)
MX (1) MX381633B (es)
NI (1) NI201800039A (es)
PE (1) PE20181165A1 (es)
PH (1) PH12018500576A1 (es)
SI (1) SI3350162T1 (es)
TW (1) TWI758255B (es)
UA (1) UA122973C2 (es)
UY (1) UY36903A (es)
WO (1) WO2017046255A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
EP3201177B1 (en) * 2014-10-01 2018-11-21 Janssen Pharmaceuticals, Inc. Mono- or di-substituted indoles as dengue viral replication inhibitors
UA121119C2 (uk) * 2014-10-01 2020-04-10 Янссен Фармасьютикалз, Інк. Похідні моно- або дизаміщених індолів як інгібітори реплікації вірусів денге
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) * 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MD3390395T2 (ro) 2015-12-16 2021-02-28 Loxo Oncology Inc Compuși utili ca inhibitori ai kinazei
CA3013407A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
SI3436435T1 (sl) 2016-03-31 2021-08-31 Janssen Pharmaceuticals, Inc. Substituirani derivati indolina kot zaviralci replikacije virusa denga
US10730884B2 (en) 2016-04-01 2020-08-04 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) * 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN110691773B (zh) 2017-05-22 2023-06-23 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物
PE20200342A1 (es) 2017-05-22 2020-02-14 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021559A1 (en) * 1997-10-27 1999-05-06 Eli Lilly And Company MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
CA2468202A1 (en) 2001-12-12 2003-06-19 Conforma Therapeutics Corporation Assays and implements for determining and modulating hsp90 binding activity
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
BRPI0606524A2 (pt) 2005-01-14 2009-06-30 Genelabs Tech Inc derivados de indol para o tratamento de infecções virais
EP1853317A2 (en) 2005-02-09 2007-11-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
AR065860A1 (es) * 2007-03-29 2009-07-08 Novartis Ag 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
CN102056483A (zh) 2008-06-03 2011-05-11 西佳技术公司 用于治疗或预防登革病毒感染的小分子抑制剂
BRPI0917394A2 (pt) * 2008-08-18 2019-09-24 Univ Yale moduladores de mif
US8143259B2 (en) 2008-08-19 2012-03-27 Janssen Pharmaceutica, Nv Cold menthol receptor antagonists
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
JP5777223B2 (ja) 2010-01-15 2015-09-09 ギリアード サイエンシーズ, インコーポレイテッド フラビウイルス科ウイルスのインヒビター
WO2011120025A1 (en) * 2010-03-26 2011-09-29 Glaxo Group Limited Indazolyl-pyrimidines as kinase inhibitors
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) * 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
EA034448B1 (ru) 2013-10-23 2020-02-10 Янссен Сайенсиз Айрлэнд Юси Производные карбоксамида и их применение в качестве медикаментов для лечения гепатита b
WO2015116885A1 (en) 2014-01-31 2015-08-06 Bristol-Myers Squibb Company Macrocycles with aromatic p2' groups as factor xia inhibitors
EP3201177B1 (en) * 2014-10-01 2018-11-21 Janssen Pharmaceuticals, Inc. Mono- or di-substituted indoles as dengue viral replication inhibitors
NO2721243T3 (es) 2014-10-01 2018-10-20
UA121119C2 (uk) 2014-10-01 2020-04-10 Янссен Фармасьютикалз, Інк. Похідні моно- або дизаміщених індолів як інгібітори реплікації вірусів денге
PH12017501272B1 (en) 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3370698B1 (en) 2015-11-03 2022-01-26 Zoetis Services LLC Sol-gel polymer composites and uses thereof
CA3013407A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
SI3436435T1 (sl) 2016-03-31 2021-08-31 Janssen Pharmaceuticals, Inc. Substituirani derivati indolina kot zaviralci replikacije virusa denga
KR102388440B1 (ko) 2016-03-31 2022-04-19 다케다 야쿠힌 고교 가부시키가이샤 헤테로시클릭 화합물
EA038878B1 (ru) 2016-04-01 2021-11-01 Басф Се Бициклические соединения
AU2017241837B2 (en) 2016-04-01 2021-07-22 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
BR112018070073A2 (pt) 2016-04-01 2019-02-12 Kite Pharma, Inc. receptores de antígeno quimérico e célula t e métodos de uso
SG11201808622SA (en) 2016-04-01 2018-10-30 Amgen Inc Chimeric receptors to flt3 and methods of use thereof
US10730884B2 (en) 2016-04-01 2020-08-04 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
CA3019650C (en) 2016-04-01 2023-07-25 Kite Pharma, Inc. Chimeric receptors and methods of use thereof
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN110691773B (zh) 2017-05-22 2023-06-23 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物
PE20200342A1 (es) 2017-05-22 2020-02-14 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue

Also Published As

Publication number Publication date
ES2893298T3 (es) 2022-02-08
HRP20211352T1 (hr) 2022-02-04
CA2996979A1 (en) 2017-03-23
CR20180213A (es) 2018-06-27
IL258043A (en) 2018-05-31
WO2017046255A1 (en) 2017-03-23
LT3350162T (lt) 2021-09-27
EA035663B1 (ru) 2020-07-23
UA122973C2 (uk) 2021-01-27
JP7050666B2 (ja) 2022-04-08
NI201800039A (es) 2018-07-24
JP2018528220A (ja) 2018-09-27
DK3350162T3 (da) 2021-10-04
MX2018003255A (es) 2018-11-09
UY36903A (es) 2017-03-31
CN108473422A (zh) 2018-08-31
EA201890722A1 (ru) 2018-09-28
CA2996979C (en) 2024-01-30
EP3350162A1 (en) 2018-07-25
IL258043B (en) 2021-08-31
MA42810A (fr) 2018-07-25
HUE055870T2 (hu) 2021-12-28
MX381633B (es) 2025-03-12
SI3350162T1 (sl) 2021-11-30
AU2016324982B2 (en) 2021-04-15
TWI758255B (zh) 2022-03-21
ECSP18020055A (es) 2018-04-30
JOP20160198B1 (ar) 2022-03-14
KR102646174B1 (ko) 2024-03-08
US10765662B2 (en) 2020-09-08
CL2018000696A1 (es) 2018-07-06
AU2016324982A1 (en) 2018-03-15
TW201722913A (zh) 2017-07-01
US20180256545A1 (en) 2018-09-13
CN108473422B (zh) 2021-06-15
PH12018500576A1 (en) 2018-10-15
JP2021181485A (ja) 2021-11-25
HK1257842A1 (en) 2019-11-01
EP3350162B1 (en) 2021-07-14
PE20181165A1 (es) 2018-07-19
KR20180052672A (ko) 2018-05-18

Similar Documents

Publication Publication Date Title
ECSP22023220A (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
CO2018003471A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue
CO2018003369A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue
ECSP18073245A (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue
ECSP18073264A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CO2019010295A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2017000782A1 (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
CO2019012035A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2019010292A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY36339A (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue